flecha

Producto

flecha
Hibor®
Hibor® (Bemiparin) is a low molecular weight heparin indicated for preventing and treating thromboembolic disease (TED), both in surgical and medical patients, and for the intense and long-term treatment of patients who have suffered a TED process.
Hibor® (Bemiparin) is a low molecular weight heparin indicated for preventing and treating thromboembolic disease (TED), both in surgical and medical patients, and for the intense and long-term treatment of patients who have suffered a TED process.

Hibor® (Bemiparin) is also indicated for preventing coagulation in the extracorporeal circuit during haemodialysis.

Hibor® (Bemiparin) has as its main feature the fact that it can be administered 2 hours before or 6 hours after surgery. Its post-surgery dosage has the advantage of reducing the risk of spinal hematoma and contributes to reducing hospital costs, as patients can be admitted on the day of surgery.

Hibor® (Bemiparin) has consolidated its position in the market for anti-thrombosis drugs as the second most-sold LMWH in Spain, with a market share of 27% at the end of December 2008 (ISM, January 2009)

Hibor® (Bemiparin) has a significant international presence. The product has been approved in 35 countries in 4 continents, has been approved and is pending marketing in another 6 countries, and is in the approval process in a further 18 countries.
 
 
Permalink  
Delicious  Technorati  Facebook  Twitter  Meneame 
Búsqueda
linea
Google Búsqueda personalizada
Área colaborativa de la BioRegión
Área colaborativa de la BioRegión
RSS
linea
RSS RSS Andalucía BioRegión
Acceso usuarios
linea
Email:
Contraseña:

Registrarse

¿Olvidó su contraseña?

Acceso empresas/centros
linea
Email:
Contraseña:

Registre su empresa

¿Olvidó su contraseña?

Nube de etiquetas
linea
Ver más etiquetas
Área colaborativa de la BioRegión